亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Dopamine Receptor Agonists

總結: Researchers at Purdue University have developed a class of novel D1 dopamine agonists, or stimulants, which may be useful in treating the symptoms of Parkinson's disease and other working memory and cognitive deficits. This series of compounds has potent and selective activity at dopamine D1 receptors, making them useful therapeutic agents in hypodopaminergic conditions. Recent studies have also shown that dopamine D1 agonists are able to reverse drug-induced and age-related deficits in working memory.

技術優勢: Novel class of dopamine agonists Potent and selective activity Clinical precedent

*Background: Dopamine is a neurotransmitter that is important in locomotor control, reward circuitry, cognitive function, prolactin release, and a variety of other key physiological functions. Dopaminergic dysfunctions have been implicated in many disorders including Parkinson's disease, schizophrenia, addiction, and ADHD. Dopamine receptor agonists are of interest in terms of finding successful therapies for these disorders. However, current D1 and D2 receptor agonists can have adverse side effects depending on the level and timing of use.

*Web Links: Purdue Office of Technology CommercializationPurdue Innovation and EntrepreneurshipDavid NicholsPurdue Medicinal Chemistry and Molecular Pharmacology

欲了解更多信息，請點擊這裡